Bacitracin

Evidence Level: L5

Predicted Indications: 10

Bacitracin

Pharmacist Assessment Report

Bacitracin: Cell wall synthesis–inhibiting topical antibiotic → punctate epithelial keratoconjunctivitis

One-Sentence Summary

Bacitracin is a topical polypeptide antibiotic that acts against Gram-positive bacteria. The TxGNN model predicts it may be useful for punctate epithelial keratoconjunctivitis, but no clinical trials and no publications directly studying this disease were found, so the prediction rests on model output alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	punctate epithelial keratoconjunctivitis
TxGNN Prediction Score	1.0000
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 5 of 5)
Number of DINs	5 (marketed: 5)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in the data compiled for this report. Bacitracin is generally known as a polypeptide antibiotic that inhibits bacterial cell wall synthesis and is most active against Gram-positive organisms. It is used in topical products, mainly ointments.

The prediction is plausibly an extension of bacitracin’s use in superficial eye infections. However, punctate epithelial keratoconjunctivitis is often viral (for example adenoviral) or non-infectious (for example toxic), and a Gram-positive-directed antibiotic would be expected to offer limited benefit in those cases. The score is high (0.9999918937683104 before rounding), but a score is a model output and not evidence of clinical benefit. No study supports this specific use.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for punctate epithelial keratoconjunctivitis.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02245571	BACIJECT	Not recorded	Not recorded
00584908	BACITIN	Not recorded	Not recorded
02451026	BACITRACIN OINTMENT	Not recorded	Not recorded
00621366	BIODERM OINTMENT	Not recorded	Not recorded
02236917	OZONOL ANTIBIOTICS PLUS	Not recorded	Not recorded

All five listed authorizations are products with valid status.

Safety Considerations

Label-based warnings and contraindications were not available in the data compiled for this report. Please refer to the package insert for full safety information.

Drug Interactions: 84 interactions were identified in the interaction database. The main ones to note:

Major: kanamycin, neomycin, streptomycin (other aminoglycosides, which raises concern for additive kidney and nerve toxicity), deferasirox, and the iodinated contrast agents diatrizoate, iodipamide, iodixanol and iohexol.
Moderate: mesalazine, balsalazide, olsalazine, sulfasalazine, vancomycin, exenatide and picosulfuric acid.

Conditions flagged as potential cautions (not from label text): kidney disease, liver disease, myasthenia gravis and other neuromuscular junction disorders, epilepsy, and several eye conditions (such as herpes simplex keratitis, viral and fungal eye infections, glaucoma and ocular hypertension). These flags need to be checked against the official label before any clinical consideration.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has no supporting trials or publications, and the likely causes of this condition (viral or non-infectious) do not match bacitracin’s antibacterial mechanism. Evidence level is L5.

To proceed, the following is needed:

Retrieval and review of the Health Canada package insert (warnings, contraindications, approved indications)
Mechanism-of-action data
Literature or clinical evidence that directly addresses punctate epithelial keratoconjunctivitis, including how often a bacterial cause is involved
Confirmation that an ophthalmic formulation and route are available
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.